Ariad Pharmaceuticals Still Might Have Upside Investorplace.com It appears they're banking heavily on approval of Ariad's leukemia treatment ponatinib in 2013. The drug garnered rave reviews at the recent American Society of Hematology meeting in San Diego, with impressive results treating study patients with ... |
Wednesday, December 21, 2011
Ariad Pharmaceuticals Still Might Have Upside - Investorplace.com
callahamirykaan1884.blogspot.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment